WO1999044583A3 - Methods and devices for modulating the immune response - Google Patents

Methods and devices for modulating the immune response Download PDF

Info

Publication number
WO1999044583A3
WO1999044583A3 PCT/US1999/004637 US9904637W WO9944583A3 WO 1999044583 A3 WO1999044583 A3 WO 1999044583A3 US 9904637 W US9904637 W US 9904637W WO 9944583 A3 WO9944583 A3 WO 9944583A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
device
immune response
immune
mammal
Prior art date
Application number
PCT/US1999/004637
Other languages
French (fr)
Other versions
WO1999044583A2 (en
Inventor
Anthony Cerami
Carla Cerami
Cohava Gelber
David Dove
Original Assignee
Applied Vaccine Technologies C
Anthony Cerami
Carla Cerami
Cohava Gelber
David Dove
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US3340298A priority Critical
Priority to US09/033,402 priority
Application filed by Applied Vaccine Technologies C, Anthony Cerami, Carla Cerami, Cohava Gelber, David Dove filed Critical Applied Vaccine Technologies C
Priority claimed from JP2000534186A external-priority patent/JP2003523308A/en
Publication of WO1999044583A2 publication Critical patent/WO1999044583A2/en
Publication of WO1999044583A3 publication Critical patent/WO1999044583A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Abstract

The present invention provides methods and devices for inducing, stimulating, blocking and reducing the immune response of a mammal to an antigen, using an implantable device which exposes the antigen in a controlled fashion to cells of the immune system. The device comprises a porous matrix contained within a perforated, impermeable container. By manipulating the bioavailability of antigen within the device, and the timing of introduction of antigen into the device relative to the time of implantation of the device within the mammal, a robust and long-term response can be induced against an antigen, or an existing or potential immune response can be down regulated or blocked. The methods and devices can be used for therapeutic vaccination, and in non-exposed mammals for prophylactic vaccination. Immunity can be cellular, humoral, or mucosal. Suppression of the immune response is useful for the treatment or prophylaxis of such conditions as allergies, autoimmune disease, and in tolerizing mammals to suppress an immune response to transplant antigens. The device can also be used for harvesting immune cells for later reintroduction into the mammal, and for preparing immune serum and hybridomas.
PCT/US1999/004637 1998-03-02 1999-03-02 Methods and devices for modulating the immune response WO1999044583A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US3340298A true 1998-03-02 1998-03-02
US09/033,402 1998-03-02

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2000534186A JP2003523308A (en) 1998-03-02 1999-03-02 Method and device for modulating the immune response
AU30667/99A AU756951B2 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
BR9908466-0A BR9908466A (en) 1998-03-02 1999-03-02 Proceso to modulate the immune response in a mammal to an antigen, inplantável device for modulating an immune response to an antigen, and processes for obtaining immune cells from a mammal, for immunizing a mammal with an antigen for the production of hybridomas producing human monoclonal antibodies against a preselected antigen, to transfecting immune cells of a mammal with genetic material, and for the treatment or prophylaxis of a disease or condition caused by an immune response
CA002322435A CA2322435A1 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
EP99912252A EP1066028A2 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
HU0101076A HU0101076A2 (en) 1998-03-02 1999-03-02 Procedures and tools to modify the immune response
KR1020007009699A KR20010041528A (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
IL138207??A IL138207D0 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
NO20004349A NO20004349L (en) 1998-03-02 2000-09-01 Methods and apparatus for modulating the immune response

Publications (2)

Publication Number Publication Date
WO1999044583A2 WO1999044583A2 (en) 1999-09-10
WO1999044583A3 true WO1999044583A3 (en) 1999-11-11

Family

ID=21870212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/004637 WO1999044583A2 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response

Country Status (4)

Country Link
BR (1) BR9908466A (en)
CA (1) CA2322435A1 (en)
IL (1) IL138207D0 (en)
WO (1) WO1999044583A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958158B2 (en) 2001-05-11 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc. Immune modulation device for use in animals
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
AU2003231234A1 (en) * 2002-05-03 2003-11-17 Children's Hospital Medical Center Simulated vernix compositions for skin cleansing and other applications
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
CA2632630C (en) 2005-12-13 2016-12-06 President And Fellows Of Harvard College Scaffolds for cell transplantation
CA2715460A1 (en) 2008-02-13 2009-08-20 President And Fellows Of Harvard College Continuous cell programming devices
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732155A (en) * 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
EP0300102A1 (en) * 1987-07-21 1989-01-25 The Stolle Research And Development Corporation Improved method of obtaining immune regulatory factors by mammal immunization
US4919929A (en) * 1984-02-01 1990-04-24 Stolle Research & Development Corporation Mammal immunization
WO1993017662A1 (en) * 1992-03-02 1993-09-16 Daratech Pty. Ltd. Improved implants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919929A (en) * 1984-02-01 1990-04-24 Stolle Research & Development Corporation Mammal immunization
US4732155A (en) * 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
EP0300102A1 (en) * 1987-07-21 1989-01-25 The Stolle Research And Development Corporation Improved method of obtaining immune regulatory factors by mammal immunization
WO1993017662A1 (en) * 1992-03-02 1993-09-16 Daratech Pty. Ltd. Improved implants

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery

Also Published As

Publication number Publication date
IL138207D0 (en) 2001-10-31
BR9908466A (en) 2000-12-05
WO1999044583A2 (en) 1999-09-10
CA2322435A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
Wilbanks et al. Studies on the induction of anterior chamber-associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood-borne signals that induce ACAID.
Brewer et al. In interleukin‐4‐deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production
Herzenberg et al. T-cell regulation of antibody responses: demonstration of allotype-specific helper T cells and their specific removal by suppressor T cells.
Buxton Toxoplasmosis: the first commercial vaccine
Klinman et al. DNA vaccines: safety and efficacy issues
CA2106492C (en) Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a
Eugui et al. Genetically restricted cell-mediated cytotoxicity in cattle immune to Theileria parva
Sjölander et al. Iscoms containing purifiedQuillajasaponins upregulate both Th1-like and Th2-like immune responses
Urquhart et al. Immunosuppression in Trypanosoma brucei infections in rats and mice
Pal et al. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge.
Yamamoto et al. Genetically Manipulated Bacterial Toxin as a New Generation Mucosal Adjuvant: FRONTLINES‐TOPIC REVIEW
DE69737218D1 (en) Adjuvant for transcutaneous immunization
DK0927024T3 (en) Device and method for the treatment of eye diseases
DK1107791T3 (en) Hydrogel preparations for controlled release administration of growth factors
ES2181798T3 (en) Method to start an immune answer in an animal one day age.
DE60209446D1 (en) Medical implant device, introducer, and implantation method for an active agent and cell-containing implant
KR977004410A (en) Implantable Device Containing Tumor Cells for the Treatment of Cancer
Wilson et al. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin
JP2010180228A (en) Vaccine for percutaneous immunization
DE60019881D1 (en) Implantable active device of the type multisite with means for resynchronizing the ventricles
BG99850A (en) Method for the cultivation of the virus of the reproductive and respiratory syndrome in pigs and its utilization for vaccine production
DK1051506T4 (en) Procedures for the extraction and insulation of bacterial capsular polyaccharides for use as vaccines or connected to projects as conjugate vaccines
DK0885244T3 (en) Peptide immunogens for vaccination against and for the treatment of allergies
DK1086137T3 (en) Composition and method for modulating dendritic T cell cell interaction
Howard et al. Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99805765.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/008532

Country of ref document: MX

ENP Entry into the national phase in:

Ref document number: 2322435

Country of ref document: CA

Ref document number: 2322435

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 138207

Country of ref document: IL

Ref document number: PV2000-3206

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020007009699

Country of ref document: KR

ENP Entry into the national phase in:

Ref document number: 2000 534186

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 506786

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 30667/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/445/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1999912252

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2000/03225

Country of ref document: TR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999912252

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007009699

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2000-3206

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 30667/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020007009699

Country of ref document: KR